FrancophonIA/ELRC3.0 huggingface dataset:
English: Blood: low red blood cell count (anaemia), drop in the number of red blood cells - the signs may include feeling tired, headaches, being short of breath when exercising; low neutrophil count (neutropenia), low number of white blood cells - the signs may include getting more infections than usual - including fever, severe chills, a sore throat or mouth ulcers
Danish: Psykisk sygdom: angstfølelse; følelse af dyb bedrøvelse eller af at være værdiløs (depression); følelse af irritabilitet, anspændthed og rastløshed Blod: lavt antal røde blodlegemer (blodmangel - anæmi), fald i antallet af røde blodlegemer (blodmangel) - tegnene kan være træthedsfølelse, hovedpine, stakåndethed under motion; lavt antal neutrofiler (neutropeni), lavt antal hvide blodlegemer - tegnene kan være, at man får flere infektioner end normalt - herunder feber, voldsomme kuldegysninger, ondt i halsen eller åbne
English: The following double amino acid substitutions conferred more than 10-fold reduced sensitivity to boceprevir: V55A+I170V, T54S+R155K, R155K+D168N, R155T+D168N and
Danish: 10 gange reduceret følsomhed over for boceprevir: V55A+I170V, T54S+R155K, R155K+D168N, R155T+D168N og V36M+R155K.
English: Please refer to the Summary of Product Characteristics for peginterferon alfa.
Danish: Se produktresumeet for peginterferon alfa.
English: Talk to your doctor or pharmacist before taking your medicine if you:
Danish: Advarsler og forsigtighedsregler Kontakt lægen eller apotekspersonalet, før du tager Victrelis, hvis du:
English: Refer to the Summary of Product Characteristics for peginterferon alfa and ribavirin for additional
Danish: Se produktresume for peginterferon alfa og ribavirin for yderligere information.
English: (CYP3A inhibition - effect on quetiapine)
Danish: (CYP3A-hæmning - indvirkning på tacrolimus)
English: Seven percent of subjects receiving the combination of Victrelis with peginterferon alfa-2b and ribavirin had neutrophil counts of < 0.5 x 10
Danish: Syv procent af de forsøgspersoner, der fik kombinationen af Victrelis og peginterferon alfa-2b og ribavirin havde
English: Goitre, hypothyroidism Hyperthyroidism
Danish: Hypertyroidisme
English: However, since the clinical relevance of the boceprevir C8h decrease has not been established, increased clinical and laboratory monitoring for HCV suppression is recommended.
Danish: Øget klinisk og laboratoriemæssig monitorering for hcv-suppression tilrådes, selvom den kliniske relevans af boceprevir-C8t-faldet ikke er klarlagt.
English: What Victrelis looks like and contents of the pack The hard capsules have a yellowish-brown cap with the "MSD" logo printed in red ink and an offwhite body with "314" printed in red ink.
Danish: De hårde kapsler har en gulbrun del med "MSD" logo trykt med rød farve og en råhvid del med koden
English: PROVIDE (P05514) was an open-label, single-arm study of Victrelis 800 mg orally three times daily in combination with PR [peginterferon alfa-2b 1.5 µg/kg/week subcutaneously and weight-based ribavirin (600 1,400 mg BID) orally divided twice daily] in adult subjects with chronic hepatitis C (HCV) genotype 1 infection who did not achieve SVR while in the PR control arms of previous Phase 2 and 3 studies of combination therapy with Victrelis.
Danish: PROVIDE (P05514) var et open-label, single-arm studie med Victrelis 800 mg oralt tre gange dagligt i kombination med PR [peginterferon alfa-2b 1,5 µg/kg/uge subkutant og vægtbaseret ribavirin (600 1.400 mg) oralt fordelt på to daglige doser] hos voksne forsøgspersoner med kronisk hepatitis C (hcv) genotype 1-infektion, der ikke opnåede SVR i PR kontrol armene i tidligere Fase 2og 3-studier af kombinationsbehandling med Victrelis.
English: Relapser: subject who failed to achieve SVR after at least 12 weeks of previous treatment with peginterferon alfa-2b and ribavirin, but had undetectable HCV-RNA at the end of treatment.
Danish: Tilbagefald: forsøgsperson, som ikke opnåede SVR efter mindst 12 ugers tidligere behandling med peginterferon alfa-2b og ribavirin, men som havde ikke-detekterbart hcv-RNA ved afslutningen af behandlingen.
English: Reminder: Please also read the “Possible side effects” in the Package Leaflets for peginterferon alfa and ribavirin before you start taking Victrelis.
Danish: Husk: Læs også afsnittet "Bivirkninger" i indlægssedlen for peginterferon alfa og ribavirin, før du
English: Papilloedema
Danish: VictrelisRGT
English: Pregnancy must be avoided due to the use of Victrelis with ribavirin.
Danish: Da Victrelis bruges sammen med ribavirin, skal graviditet undgås.
English: Ten percent of subjects (17/168) were cirrhotic, including 3 (6%) prior null responders, 2 (7%) prior relapsers, and
Danish: Forsøgspersonerne indbefattede 62 % (104/168) genotype 1a og 38 % (63/168) genotype 1b. Ti procent af forsøgspersonerne (17/168) var cirrotiske, herunder 3 (6 %) tidligere null-responders, 2 (7 %) med tidligere tilbagefald og 12 (14 %) med tidligere delvis respons.
English: The safety and efficacy of Victrelis alone or in combination with peginterferon alfa and ribavirin for the treatment of chronic hepatitis C genotype 1 infection in liver or other organ transplant recipients have not been studied (see section 4.5).
Danish: Victrelis' sikkerhed og virkning alene eller i kombination med peginterferon alfa og ribavirin til behandling af kronisk hepatitis C-genotype 1-infektion i lever- eller andre organtransplantatmodtagere er ikke undersøgt (se pkt.
English: Eyes or ears: pink eye; eye pain; deafness; trouble hearing; swelling around the eyelid; increased tearing; fluid draining from the ear or eye; abnormal feeling around the eye, red patch on the white of the eye; yellowing of the white part of the eyes or of the skin Mouth, nose or throat: hoarseness, dry throat or lips; painful or bleeding gums; sensitive tooth or toothache; tongue swollen, discoloured, or has sores; blistering by the tongue; severe pain when swallowing; chest pain close to the lungs; chest pain worsens when taking a deep breath; uncontrolled salivating; overactive thyroid gland Skin and hair: hives; open sore; intolerance to heat; markedly red face; pale face; yellow skin; rash due to sunlight; wound not healing normally Feet or hands or legs or arms: sensation of pain, numbness, tingling or prickling; blood clot in a vein; feeling cold in an arm or leg; painful inflammation of the joints most commonly in the foot (gout)
Danish: Ikke almindelig: (kan berøre op til 1 ud af 100) Generelt: svimmelhed, leddegigt; øget tilbøjelighed til at bløde; hævede kirtler i halsen eller under armene eller i lysken; kraftig brænden eller stikkende smerte; øget følsomhed over for lys, lyd, det, man kan føle eller den mad, man smager; sukkersyge (diabetes mellitus) Øjne eller ører: øjenbetændelse; øjensmerter; døvhed; problemer med at høre; hævelse omkring øjenlåget; øget tårestrøm; dryppende væske fra øret eller øjet; unormal følelse omkring øjet, rød plet på det hvide i øjet; gulfarvning af det hvide i øjnene eller af huden Mund, næse eller svælg: hæshed, tør hals eller tørre læber; smerter i eller blødende gummer; følsomme tænder eller tandpine; hævet eller misfarvet tunge eller sår på tungen; blærer på tungen; voldsomme smerter ved synkning; brystsmerter i nærheden af lungerne; brystsmerter tager til ved dyb indånding; ukontrolleret savlen; overaktiv skjoldbruskkirtel Hud og hår: udslæt; åbne sår; varmeintolerans; markant rødt ansigt; blegt ansigt; gul hud; udslæt på grund af sollys; sår, som ikke heler som normalt Fødder, hænder, ben eller arme: følelse af smerte, følelsesløshed, snurren eller prikken; blodprop i en vene; følelse af kulde i en arm eller et ben; smertefuld betændelse i leddene,
English: Maximum daily dose of Victrelis is 2,400 mg. Administration without food could be associated with a net loss of efficacy due to sub-optimal exposure.
Danish: Tages kapslerne uden mad, kan det resultere i, at den samlede virkning nedsættes på grund af suboptimal eksponering.
English: Chest discomfort*, chest pain*, malaise*, feeling of body temperature change, mucosal dryness, pain Feeling abnormal, impaired healing, non-cardiac chest
Danish: Ubehag i bryst*, brystsmerter*, utilpashed*, følelse af kropstemperaturændringer, tørhed af slimhinde, smerter
English: boceprevir AUC ↓ 5% boceprevir Cmax ↑ 4%
Danish: boceprevir AUC ↓ 5 % boceprevir Cmaks.
English: The Full Analysis Set (FAS) consisted of all randomized subjects (N=1,097) who received at least one dose of any study medicine (peginterferon alfa-2b, ribavirin, or Victrelis).
Danish: Full Analysis Set (FAS) bestod af alle randomiserede forsøgspersoner (N=1.097), som fik mindst én dosis studiemedicin (peginterferon alfa-2b, ribavirin eller Victrelis).
English: In subjects treated with boceprevir, interferon responsiveness (as defined by ≥ 1-log10 decline in viral load at Treatment Week 4) was associated with detection of fewer RAVs, with 6% of these subjects having RAVs compared to 41% of subjects with < 1-log10 decline in viral load at Treatment Week 4 (poorly interferon responsive).
Danish: Blandt 6 % af disse forsøgspersoner blev RAVer påvist, sammenlignet med 41 % af forsøgspersonerne med < 1 log10 fald i viral-load i behandlingsuge 4 (med ringe interferonfølsomhed).
English: Clinical Study
Danish: Undersøgelser
English: o Subjects with a detectable HCV-RNA at TW 8 but subsequently undetectable at TW 12 (late responders) were changed in a blinded fashion to placebo at the TW 36 visit and continued treatment with peginterferon alfa-2b + ribavirin for an additional 12 weeks, for a total treatment duration of 48 weeks.
Danish: Behandlingen i denne behandlingsgruppe var begrænset til 32 ugers behandling o Hos forsøgspersoner med ikke-detekterbart hcv-RNA i behandlingsuge 8 (tidlige respondenter) og behandlingsuge 12 afsluttedes behandlingen ved kontrolbesøget i o Forsøgspersoner med detekterbart hcv-RNA i behandlingsuge 8, som efterfølgende havde ikke-detekterbart hcv-RNA i behandlingsuge 12 (sene respondenter), blev under blinding skiftet til placebo ved kontrolbesøget i behandlingsuge 36 og fortsatte behandlingen med peginterferon alfa-2b + ribavirin i yderligere 12 uger til en samlet behandlingsvarighed på 48 uger.
English: Previous Partial Responder = subject who failed to achieve SVR after at least 12 weeks of previous treatment with peginterferon alfa and ribavirin, but demonstrated a ≥ 2 log10 reduction in HCV-RNA by Week 12 and had detectable HCV-RNA at End of Treatment (EOT).
Danish: Tidligere delvis respons = forsøgsperson, der ikke opnåede SVR efter mindst 12 ugers tidligere behandling med peginterferon alfa og ribavirin, men hvor et ≥ 2 log10-fald i hcv-RNA blev påvist i uge 12 og som havde detekterbart hcv-RNA ved afslutningen af behandlingen (EOT).
English: RESPOND-2 (P05101) was a randomized, parallel-group, double-blinded study comparing two therapeutic regimens of Victrelis 800 mg orally three times daily in combination with PR [peginterferon alfa-2b 1.5 µg/kg/week subcutaneously and weight-based ribavirin (600 1,400 mg BID) orally divided twice daily] compared to PR alone in adult subjects with chronic hepatitis C HCV genotype 1 infection with demonstrated interferon responsiveness (as defined historically by a decrease in HCV-RNA viral load ≥ 2 log10 by Week 12 or undetectable HCV-RNA at end of prior treatment with a subsequent detectable HCV-RNA in plasma) and who failed prior treatment with peginterferon alfa and ribavirin.
Danish: RESPOND-2 (P05101) var et randomiseret, dobbeltblindet studie med parallelle grupper, der sammenlignede to behandlingsregimer med Victrelis 800 mg oralt tre gange dagligt i kombination med PR [peginterferon alfa-2b 1,5 µg/kg/uge subkutant og vægtbaseret ribavirin (600 1.400 mg to gange dagligt) oralt fordelt på to daglige doser] sammenlignet med PR alene hos voksne forsøgspersoner med kronisk hepatitis C hcv genotype 1-infektion med påvisning af interferonfølsomhed (historisk defineret som fald i hcv-RNA viral-load ≥ 2 log10 i uge 12 eller ikkedetekterbart hcv-RNA ved afslutning af tidligere behandling med efterfølgende detekterbart hcv-RNA i plasma), og hvor tidligere behandling med peginterferon alfa og ribavirin havde svigtet.
English: All subjects n=368
Danish: n=368
English: Infections and infestations Common:
Danish: Metabolisme og ernæring Meget almindelig:
English: ‡ % (n/N) 95% CI EOT(Undetectable HCV-RNA) % (n/N) 95% CI
Danish: EOT (Ikke-detekterbart hcv-RNA) % (n/N)
English: Retinal ischaemia*, retinopathy*, abnormal sensation in eye, conjunctival haemorrhage, conjunctivitis, eye pain, eye pruritus, eye swelling, eyelid oedema, lacrimation increased, ocular hyperaemia, photophobia
Danish: Tørre øjne, retinal ekssudat, sløret syn, forringet syn Retinal iskæmi*, retinopati*, unormal følsomhed i øjet, konjunktiv blødning, konjunktivitis, smerter i øjet, øjenpruritus, hævede øjne, øjenlågsødem, øget tåresekretion, okulær hyperæmi, fotofobi
English: Relapse %(n/N) * The Full Analysis Set (FAS) consisted of all randomized subjects (N=98) who received at least one dose of any study medicine (peginterferon alfa-2b, ribavirin, or Victrelis).
Danish: Tilbagefald % (n/N) * Fuldt analysesæt (Full Analysis Set) bestod af alle randomiserede forsøgspersoner (N=98), der fik mindst én dosis studiemedicin (peginterferon alfa--2b, ribavirin eller Victrelis).
English: Skin and subcutaneous tissue disorders Very common:
Danish: Luftveje, thorax og mediastinum Meget almindelig:
English: Boceprevir also undergoes, to a lesser extent, oxidative metabolism
Danish: Boceprevir gennemgår også, i mindre grad, oxidativ metabolisme medieret af CYP3A4/5.
English: • are taking bepridil, pimozide, lurasidone, oral midazolam, oral triazolam, simvastatin, lovastatin, alfuzosin, silodosin, 'ergot' type medicines (such as dihydro-ergotamine, ergonovine, ergotamine or methylergonovine), lumefantrine, halofantrine, quetiapine, or tyrosine kinase inhibitors.
Danish: alfuzosin, silodosin, medicin af sekale-typen (såsom dihydroergotamin, ergonovin, ergotamin eller methylergonovin), lumefantrin, halofantrin, quetiapin eller tyrosinkinasehæmmere.
English: %(n/N) * The Intent-to-Treat (ITT) population consisted of all subjects (N=168) who received at least one dose of any study medicine (peginterferon alfa-2b, ribavirin, or Victrelis).
Danish: * Intent-to-Treat-populationen (ITT) bestod af alle forsøgspersoner (N=168), som fik mindst en dosis studiemedicin (peginterferon alfa-2b, ribavirin eller Victrelis).
English: It is not known whether boceprevir is excreted in human breast milk.
Danish: Det er ukendt, om boceprevir udskilles i
English: The proportion of subjects who received a transfusion for the management of anaemia was 3% of subjects in the Victrelis-containing arms compared to < 1% of subjects receiving peginterferon alfa-2b and ribavirin alone.
Danish: Andelen af forsøgspersoner, der fik transfusion til håndtering af anæmi var 3 % af forsøgspersonerne i de Victrelis-indeholdende arme sammenlignet med < 1 % af forsøgspersonerne, der kun fik
English: In particular, do not take Victrelis if you are taking any of the following medicines: • alfuzosin and silodosin - used to treat symptoms of an enlarged prostate
Danish: • alfuzosin og silodosin - bruges til behandling af symptomer på forstørret prostata
English: Previous Relapser = subject who failed to achieve SVR after at least 12 weeks of previous treatment with peginterferon alfa and ribavirin, but had undetectable HCV-RNA at the end of treatment.
Danish: Tidligere tilbagefald = forsøgsperson, der ikke opnåede SVR efter mindst 12 ugers tidligere behandling med peginterferon alfa og ribavirin, men havde ikke-detekterbart hcv-RNA ved
English: Rilpivirine* (rilpivirine 25 mg every 24 hours + Victrelis 800 mg three times daily)
Danish: Etravirin* (etravirin 200 mg hver 12. time + Victrelis 800 mg tre gange dagligt)
English: SPRINT-2 (P05216) was a randomized, double blinded, placebo-controlled study comparing two therapeutic regimens of Victrelis 800 mg orally three times daily in combination with PR [peginterferon alfa-2b 1.5 µg/kg/week subcutaneously and weight-based dosing with ribavirin (6001,400 mg/day orally divided twice daily)] to PR alone in adult subjects who had chronic hepatitis C HCV genotype 1 infection with detectable levels of HCV-RNA and were not previously treated with interferon alfa therapy.
Danish: SPRINT-2 (P05216) var et randomiseret, dobbeltblindet, placebo-kontrolleret studie, der sammenlignede to behandlingsregimer med Victrelis 800 mg oralt tre gange dagligt i kombination med PR [peginterferon alfa-2b 1,5 µg/kg/uge subkutant og vægtbaseret dosering med ribavirin (6001.400 mg/dag oralt fordelt på to daglige doser)] med PR alene hos voksne forsøgspersoner, der havde kronisk hepatitis C hcv genotype 1-infektion med detekterbare niveauer af hcv-RNA, og som ikke tidligere var blevet behandlet med interferon alfa.
English: P05411 was a phase II randomized, double-blind, placebo-controlled study comparing Victrelis 800 mg orally three times daily in combination with PR [peginterferon alfa-2b 1.5 µg/kg/week subcutaneously and weight-based dosing with ribavirin (600-1,400 mg/day orally)] to PR alone in subjects co-infected with HIV and HCV genotype 1 who were previously untreated for chronic HCV infection.
Danish: P05411 var et randomiseret, dobbeltblindet, placebokontrolleret fase-II studie, hvor Victrelis 800 mg oralt 3 gange dagligt i kombination med PR [peginterferon alfa-2b 1,5 µg/kg/uge subkutant og vægtbaseret dosering med ribavirin (600-1.400 mg/dag oralt)] blev sammenlignet med PR alene hos forsøgspersoner, der var co-inficeret med hiv og hcv genotype-1, og som ikke tidligere var blevet behandlet for kronisk hcv-infektion.
English: ethinyl estradiol AUC ↓ 26% ethinyl estradiol Cmax ↓ 21%
Danish: ethinylestradiol AUC ↓ 24 %
English: A randomized, parallel-arm, open-label study (P06086) was conducted to compare two strategies for the management of anaemia (use of erythropoietin versus ribavirin dose reduction) in 687 subjects including 60 cirrhotic patients with previously untreated CHC genotype 1 infection who became anaemic during therapy with Victrelis 800 mg orally three times daily in combination with PR [peginterferon alfa-2b 1.5 µg/kg/week subcutaneously and weight-based ribavirin (600 1,400 mg
Danish: Et randomiseret åbent studie med parallelle arme (P06086) blev udført for at sammenligne to strategier til behandling af anæmi (erythropoietin versus reduktion af ribavirindosis) hos 687 forsøgspersoner, herunder 60 cirrosepatienter, med tidligere ubehandlet CHC genotype 1-infektion.
English: Reminder: Please also read the “Pregnancy and breast-feeding” section of the Package Leaflets for peginterferon alfa and ribavirin before you start taking Victrelis.
Danish: Husk: Læs også afsnittet "Graviditet og amning" i indlægssedlerne for peginterferon alfa og ribavirin,
English: boceprevir AUC ↓ 45% boceprevir Cmax ↓ 50% boceprevir Cmin ↓ 57%
Danish: ↓ 25 % boceprevir Cmin ↓ 35 %
English: %, (n/N) EOT %, (n/N) Relapse
Danish: SVR %, (n/N) EOT %, (n/N) Tilbagefald %, (n/N)
English: The Full Analysis Set (FAS) consisted of all randomized subjects (N=403) who received at least one dose of any study medicine (peginterferon alfa-2b, ribavirin, or Victrelis).
Danish: Fuldt analysesæt (Full Analysis Set) bestod af alle randomiserede forsøgspersoner (N=403), der fik mindst én dosis studiemedicin (peginterferon alfa--2b, ribavirin eller Victrelis).
English: The proportion of subjects with decreased neutrophils was higher in the Victrelis-containing arms compared to subjects receiving only peginterferon alfa-2b and ribavirin.
Danish: Neutropeni var hyppigere blandt forsøgspersoner behandlet med Victrelis sammenlignet med forsøgspersoner, der kun fik peginterferon alfa-2b og ribavirin.
English: No dose adjustment of omeprazole or Victrelis is recommended.
Danish: Dosisjustering af omeprazol eller Victrelis er ikke nødvendig.
English: Epistaxis, nasal congestion, oropharyngeal pain, respiratory tract congestion, sinus congestion, wheezing Pleuritic pain*, pulmonary embolism*, dry throat, dysphonia, increased upper airway secretion, oropharyngeal blistering
Danish: Pleural smerte*, lungeembolisme*, tør hals, dysfoni, øget sekretion fra øvre luftveje, orofaryngeal blæredannelse
English: ANTI-INFECTIVES Antifungals
Danish: Patienter med hiv co-infektion
English: 3 mg daily + ethinyl estradiol 0.02 mg daily + Victrelis 800 mg three times daily)
Danish: Norethisteron†/ethinylestradiol: (norethisteron 1 mg dagligt + ethinylestradiol 0,035 mg dagligt + Victrelis 800 mg tre gange dagligt)
English: Sími: +354 535 7000
Danish: Tel: 0800 9999000
English: • Peginterferon alfa-2b + ribavirin for 4 weeks followed by Victrelis 800 mg three times daily + peginterferon alfa-2b + ribavirin for 44 weeks (Victrelis-PR48).
Danish: • Peginterferon alfa-2b + ribavirin i 4 uger efterfulgt af Victrelis 800 mg 3 gange dagligt + peginterferon alfa-2b + ribavirin i 44 uger (Victrelis-PR48).
English: boceprevir AUC ↔ boceprevir Cmax ↓ 3%
Danish: boceprevir AUC ↓ 32 % boceprevir Cmaks.
English: The safety and efficacy of Victrelis alone or in combination with peginterferon alfa and ribavirin for the treatment of chronic hepatitis C genotype 1 infection in patients co-infected with hepatitis B virus
Danish: Victrelis' sikkerhed og virkning alene eller i kombination med peginterferon alfa og ribavirin til behandling af kronisk hepatitis C-genotype 1-infektion er ikke undersøgt hos patienter, der er coinficerede med hepatitis B-virus (hbv) og hcv.
English: • Peginterferon alfa-2b + ribavirin for four weeks followed by Victrelis 800 mg three times daily + peginterferon alfa-2b + ribavirin for 44 weeks (Victrelis-PR48).
Danish: • Peginterferon alfa-2b + ribavirin i fire uger efterfulgt af Victrelis 800 mg 3 gange dagligt + peginterferon alfa-2b + ribavirin i 44 uger (Victrelis-PR48).
English: Stomach and gut: pain in stomach and in the upper right side of the stomach or back; a burning feeling in the stomach, upset stomach; feeling bloated, burping (belching) Anus: wind (flatulence); piles (haemorrhoids); difficulty passing stools (constipation) Urinary: going to the toilet to urinate more often than usual Sexual: a decrease in sex drive; difficulty getting or keeping an erection Mental illness: changes in mood, feeling agitated; memory loss, trouble concentrating Chest: difficulty breathing; chest discomfort, chest pain; heavy feeling in the chest, with
Danish: Mave og tarme: mavesmerter i den øverste højre side af maven eller smerter i ryggen; en brændende følelse i maven, uorden i maven; følelse af oppustethed, bøvsen (ræben) Anus: luft i maven; hæmorider; hård afføring (forstoppelse) Urin: går oftere på toilettet for at tisse end normalt Seksuelt: aftagen sexlyst; problemer med at få eller bibeholde rejsning Psykisk sygdom: humørsvingninger; føle sig ophidset; hukommelsestab, koncentrationsbesvær Brystet: problemer med at trække vejret; brystgener, brystsmerter; tung følelse i brystet og problemer med at trække vejret eller hvæsende vejrtrækning Hjerte eller kredsløb: hurtig eller ujævn hjerterytme; for højt eller lavt blodtryk Blod: fald i antallet af blodplader- tegnene kan være, at man får blødning eller blå mærker nemmere end normalt; højt blodsukkerniveau (glucose); høje triglyceridniveauer i blodet; høje urinsyreniveauer i blodet; en kombination af lavt antal blodplader, hvide og røde blodlegemer (pancytopeni); alvorligt fald i antallet af hvide blodlegemer (agranulocytose)
English: Dermatitis, eczema, erythema, hyperhidrosis, night sweats, oedema peripheral, psoriasis, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, skin lesion
Danish: Alopeci, tør hud, pruritus, udslæt Dermatitis, eksem, erytem, hyperhidrose, natlige svedeture, perifert ødem, psoriasis, erytematøst udslæt, maculært udslæt, maculo-papuløst udslæt, papuløst udslæt, pruritisk udslæt, hudlæsion Fotosensitiv reaktion, hud ulcus, urticaria (se pkt.